China's medical products administrator approved Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) clinical trial for its SKB535 drug for advanced solid tumors, according to a Monday filing with the Hong Kong Exchange.
SKB535 is the NMPA's first approved pilot project under the agency's optimized clinical trial review scheme.
SKB signed a license and collaboration agreement with MSD for the development of SKB535 and will be entitled to milestone payments and other royalties from net sales, the filing said.
Shares fell 4% during Monday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments